PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announces that it is presenting the initial results of its Phase I-II trial of M-Vax™ for patients with metastatic melanoma at a Clinical Research session of the meeting of the American Association for Cancer Research. M-Vax™ is composed of autologous melanoma cells that have been irradiated and then modified with the hapten, dinitrophenyl (DNP).
